TY - JOUR
T1 - Application of pyrosequencing to the identification of sequence variations in the cystic fibrosis transmembrane conductance regulator gene
AU - Mari, Caterina
AU - Bruno, Francesca
AU - Galbiati, Silvia
AU - Torri, Anna
AU - Lombardo, Federica
AU - Seia, Manuela
AU - Ferrari, Maurizio
AU - Restagno, Gabriella
AU - Cremonesi, Laura
PY - 2009/9/1
Y1 - 2009/9/1
N2 - Background: A high number of mutations associated with cystic fibrosis have been identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, most of which are rare and, therefore, hamper extensive molecular diagnosis. In couples undergoing prenatal diagnosis where no mutation is found in one or both partners, additional analysis of intragenic polymorphisms may allow for the identification of fetal alleles associated with cystic fibrosis. Methods: We developed novel, rapid and accurate assays for CFTR genotype determination using pyrosequencing technology; a simple, automated and reliable technique with low cost. Results: Assays were optimized for the identification of the seven most frequent CFTR mutations (p.DeltaF508, p.N1303K, p.G542X, c.2183AA>G, c.1717-1G>A, p.W1282X, p.R1162X) in the Italian population and two common intragenic polymorphisms (rs213950 and rs1800136). Blind validation on 15 known control samples, typed for each sequence variation, allowed correct identification of all 135 genotypes. Conclusions: We demonstrated that this procedure is highly specific for the identification of individual CFTR sequence variations associated with cystic fibrosis, allowing both population screening and prenatal diagnosis. Clin Chem Lab Med 2009;47:1051-4.
AB - Background: A high number of mutations associated with cystic fibrosis have been identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, most of which are rare and, therefore, hamper extensive molecular diagnosis. In couples undergoing prenatal diagnosis where no mutation is found in one or both partners, additional analysis of intragenic polymorphisms may allow for the identification of fetal alleles associated with cystic fibrosis. Methods: We developed novel, rapid and accurate assays for CFTR genotype determination using pyrosequencing technology; a simple, automated and reliable technique with low cost. Results: Assays were optimized for the identification of the seven most frequent CFTR mutations (p.DeltaF508, p.N1303K, p.G542X, c.2183AA>G, c.1717-1G>A, p.W1282X, p.R1162X) in the Italian population and two common intragenic polymorphisms (rs213950 and rs1800136). Blind validation on 15 known control samples, typed for each sequence variation, allowed correct identification of all 135 genotypes. Conclusions: We demonstrated that this procedure is highly specific for the identification of individual CFTR sequence variations associated with cystic fibrosis, allowing both population screening and prenatal diagnosis. Clin Chem Lab Med 2009;47:1051-4.
KW - Genotyping CFTR mutations and polymorphisms
KW - Mutational screening
KW - Pyrosequencing
UR - http://www.scopus.com/inward/record.url?scp=70349508937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349508937&partnerID=8YFLogxK
U2 - 10.1515/CCLM.2009.262
DO - 10.1515/CCLM.2009.262
M3 - Article
C2 - 19728845
AN - SCOPUS:70349508937
VL - 47
SP - 1051
EP - 1054
JO - Clinical Chemistry and Laboratory Medicine
JF - Clinical Chemistry and Laboratory Medicine
SN - 1434-6621
IS - 9
ER -